LabCorp/ARCA biopharma GENETIC-AF Poster Presented At The 18th Annual Scientific Meeting Of The Heart Failure Society Of America

ARCA biopharma, Inc. (ARCA) (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that a joint Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH) and ARCA personalized medicine abstract was presented yesterday evening at the 18th Annual Scientific Meeting of the Heart Failure Society of America, being held September 14-17, 2014 in Las Vegas, Nevada. The poster describes the genetic test that is being used to select patients for GENETIC-AF, a Phase 2B/3 adaptive design clinical trial. The GENETIC-AF trial will evaluate Gencaro™ (bucindolol hydrochloride) as a potential treatment for the prevention of atrial fibrillation (AF) in patients with heart failure and left ventricular dysfunction who also have a specific genotype of the beta-1 adrenergic receptor (389 arginine homozygous), which ARCA believes is present in approximately 50% of the U.S. population. LabCorp is performing the genetic testing for the GENETIC-AF trial.

Help employers find you! Check out all the jobs and post your resume.